Finally, butyrate has been proposed to ameliorate PD manifestations through both its HDAC-inhibitor activity and its direct impact on mitochondrial function, especially its ability to decrease the detrimental effects of ceramides that have recently emerged as potential drivers of PD pathophysiology [76,214]. The gene discussed is HDAC9; the disease is Parkinson disease.